<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02471664</url>
  </required_header>
  <id_info>
    <org_study_id>TPMMLC</org_study_id>
    <nct_id>NCT02471664</nct_id>
  </id_info>
  <brief_title>Mitral Loop Cerclage(MLC) for Reducing Functional Mitral Regurgitation</brief_title>
  <official_title>The Study on Safety and Feasibility of Mitral Loop Cerclage(MLC) Annuloplasty Procedure With Investigational Medical Device (MLC-B-45-75-R and Other 11 Models) : Single-centre, Open Label, Single Arm, Feasibility Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tau Pnu Medical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tau Pnu Medical Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety and feasibility of Mitral Loop Cerclage(MLC) Annuloplasty with CSTV for
      repair of functional mitral regurgitation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this prospective, single-center, open label, feasibility test is to assess
      the safety and efficacy of Mitral Loop Cerclage Annuloplasty with CSTV protective device in
      treating functional mitral regurgitation (FMR) associated with heart failure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of mitral regurgitation severity by regurgitant volume (RV) and effective regurgitant orifice (ERO)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in mitral annulus geometry (septal lateral dimension)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adverse events as a measure of safety</measure>
    <time_frame>1 month</time_frame>
    <description>Rate of composite endpoint of MACE (Major Adverse Cardiac Event)
* Death, myocardial infarction, cardiac tamponade, device related cardiac surgery, stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of mitral regurgitation severity by regurgitant volume (RV) and effective regurgitant orifice (ERO)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mitral annulus geometry (septal lateral dimension)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mitral valve hemodynamics</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricle volumes</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjects' symptoms referred to NYHA (New York Heart Association) Classification System</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success rate of the implantation and technical feasibility</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events as a measure of safety</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of composite endpoint of MACE (Major Adverse Cardiac Event)
* Death, myocardial infarction, cardiac tamponade, device related cardiac surgery, stroke</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Functional Mitral Regurgitation</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitral Loop Cerclage Annuloplasty</intervention_name>
    <arm_group_label>Single</arm_group_label>
    <other_name>MLC series (MLC-B-45-75-R and other 11 models)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NYHA(New York Heart Association) Class III - IV, and symptomatic severe functional MR
             by 2014 ACC/AHA guideline in spite of optimal medical treatment.

        (For optimal medical treatments, ①ACE inhibitor or angiotensin receptor blocker ②β-blocker
        ③ aldosterone antagonists should be given for at least 3 months unless the subject has
        contraindication for each drug)

        Exclusion Criteria:

          -  Primary Mitral Regurgitation

          -  LV ejection fraction lower than 25%

          -  Creatinine ≥2.0 mg/dL

          -  Anomaly of Coronary Sinus

          -  Pre-existing devices in coronary sinus such as Implantable Cardioverter Defibrillator
             and Pacemaker

          -  2:1 Atriventricular AV block or higher AV block and ventricular tachycardia

          -  Subjects with functional MR who need CABG or AVR performed

          -  Subjects who have functional MR caused by aortic valve disease

          -  Subjects who have uncontrollable hyperthyroidism

          -  Subjects who have severe TR due to primary valve leaflet disease

          -  Subjects who cannot be screened by cardiac CT

          -  Subjects who have possibility of coronary artery pinching even with Mitral Loop
             Cerclage system judged by cardiac CT

          -  Subjects who are unable to take anti-platelet agents

          -  Subjects who are participated in other clinical trials within 1 month of enrollment

          -  Subjects who have coagulation disorders

          -  Subjects who have thrombosis and embolism

          -  Subjects who are pregnant, or lactating, or plan pregnancy during the clinical trials

          -  Subjects who are deemed not to be eligible in this study by physician's discretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>June-Hong Kim, MD, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Yangsan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institues of Health</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeongsangnamdo</state>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://content.onlinejacc.org/article.aspx?articleid=1139949</url>
    <description>Mitral cerclage annuloplasty, a novel transcatheter treatment for secondary mitral valve regurgitation: Initial results in swine</description>
  </link>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S1936879817301498?via%3Dihub</url>
    <description>Mitral Loop Cerclage Annuloplasty for Secondary Mitral Regurgitation: First Human Results</description>
  </link>
  <reference>
    <citation>Kim JH, Kocaturk O, Ozturk C, Faranesh AZ, Sonmez M, Sampath S, Saikus CE, Kim AH, Raman VK, Derbyshire JA, Schenke WH, Wright VJ, Berry C, McVeigh ER, Lederman RJ. Mitral cerclage annuloplasty, a novel transcatheter treatment for secondary mitral valve regurgitation: initial results in swine. J Am Coll Cardiol. 2009 Aug 11;54(7):638-51. doi: 10.1016/j.jacc.2009.03.071.</citation>
    <PMID>19660696</PMID>
  </reference>
  <results_reference>
    <citation>Park YH, Chon MK, Lederman RJ, Sung SC, Je HG, Choo KS, Lee SH, Shin ES, Kim JS, Hwang KW, Lee SY, Chun KJ, Kim CM, Kim JH. Mitral Loop Cerclage Annuloplasty for Secondary Mitral Regurgitation: First Human Results. JACC Cardiovasc Interv. 2017 Mar 27;10(6):597-610. doi: 10.1016/j.jcin.2016.12.282.</citation>
    <PMID>28335897</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2015</study_first_submitted>
  <study_first_submitted_qc>June 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2015</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Yangsan Hospital</investigator_affiliation>
    <investigator_full_name>June-Hong Kim, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Percutaneous mitral valve repair</keyword>
  <keyword>Coronary sinus annuloplasty</keyword>
  <keyword>Mitral loop cerclage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

